NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free PLX Stock Alerts $1.24 +0.06 (+5.08%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$1.16▼$1.2450-Day Range$1.13▼$1.6352-Week Range$1.09▼$3.55Volume202,161 shsAverage Volume329,080 shsMarket Capitalization$90.58 millionP/E Ratio24.80Dividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media Get Protalix BioTherapeutics alerts: Email Address Protalix BioTherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside736.8% Upside$10.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth478.57%From $0.14 to $0.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector466th out of 910 stocksBiological Products, Except Diagnostic Industry71st out of 153 stocks 3.5 Analyst's Opinion Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtalix BioTherapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PLX. Previous Next 0.0 Dividend Strength Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PLX. Previous Next 0.6 News and Social Media Coverage Search Interest5 people have searched for PLX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.97% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.53% of the stock of Protalix BioTherapeutics is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 478.57% in the coming year, from $0.14 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is 23.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is 23.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.70.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Protalix BioTherapeutics Stock (NYSE:PLX)Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Read More PLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLX Stock News HeadlinesMarch 16, 2024 | seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | uk.investing.comEarnings call: Protalix BioTherapeutics reports fiscal year 2023 resultsApril 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 15, 2024 | ca.finance.yahoo.comProduction cuts, geopolitical tensions drive oil rallyMarch 15, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comPLX: Elfabrio Geographic ExpansionMarch 14, 2024 | finanznachrichten.deProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsMarch 14, 2024 | finance.yahoo.comProtalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023April 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 14, 2024 | prnewswire.comProtalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsMarch 13, 2024 | markets.businessinsider.comHere's what Wall Street expects from Protalix BioTherapeutics's earnings reportMarch 13, 2024 | benzinga.comEarnings Preview: Protalix BioTherapeuticsMarch 9, 2024 | edition.cnn.comProtalix Biotherapeutics, Inc.March 7, 2024 | finance.yahoo.comProtalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024February 23, 2024 | prnewswire.comProtalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor ConferenceFebruary 17, 2024 | ca.finance.yahoo.comPLX Mar 2024 1.500 callFebruary 2, 2024 | msn.comAbeona issues update on FDA market application for pz-celJanuary 25, 2024 | entrepreneur.comWill These 3 Biotech Stocks Make Gains in 2024?December 26, 2023 | finance.yahoo.comProtalix BioTherapeutics Issues 2024 Letter to StockholdersDecember 15, 2023 | benzinga.comProtalix BioTherapeutics Stock (AMEX:PLX) Insider TradesNovember 7, 2023 | finance.yahoo.comPLX: More Regulatory ApprovalsNovember 7, 2023 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call TranscriptNovember 6, 2023 | msn.comAmerican Well, Protalix BioTherapeutics among healthcare moversNovember 6, 2023 | msn.comProtalix BioTherapeutics GAAP EPS of -$0.04 beats by $0.03, revenue of $10.35M beats by $2.71MNovember 6, 2023 | washingtonpost.comProtalix: Q3 Earnings SnapshotNovember 6, 2023 | markets.businessinsider.comProtalix BioTherapeutics Inc. Q3 loss drops in line with estimatesNovember 6, 2023 | finance.yahoo.comProtalix BioTherapeutics Reports Third Quarter 2023 Financial and Business ResultsSee More Headlines Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/23/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:PLX CUSIPN/A CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees208Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+736.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.05 Trailing P/E Ratio23.90 Forward P/E Ratio8.54 P/E GrowthN/ANet Income$8.31 million Net Margins12.69% Pretax Margin13.08% Return on Equity29.73% Return on Assets10.17% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.12 Sales & Book Value Annual Sales$65.49 million Price / Sales1.33 Cash Flow$0.14 per share Price / Cash Flow8.43 Book Value$0.47 per share Price / Book2.54Miscellaneous Outstanding Shares73,050,000Free Float69,421,000Market Cap$87.29 million OptionableOptionable Beta0.89 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Dror Bashan (Age 57)President, CEO & Director Comp: $473.16kMr. Eyal Rubin M.B.A. (Age 48)Senior VP, CFO, Treasurer & Corporate Secretary Comp: $813.73kMr. Yaron Naos (Age 60)Senior Vice President of Operations Comp: $409.95kMs. Yael FellousVice President of Human ResourcesKey CompetitorsAtara BiotherapeuticsNASDAQ:ATRACEL-SCINYSE:CVMAlloVirNASDAQ:ALVRSangamo TherapeuticsNASDAQ:SGMOCognition TherapeuticsNASDAQ:CGTXView All CompetitorsInsiders & InstitutionsBailard Inc.Bought 68,100 shares on 2/2/2024Ownership: 0.095%Dror BashanBought 64,516 shares on 10/19/2023Total: $90,322.40 ($1.40/share)View All Insider TransactionsView All Institutional Transactions PLX Stock Analysis - Frequently Asked Questions Should I buy or sell Protalix BioTherapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Protalix BioTherapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLX shares. View PLX analyst ratings or view top-rated stocks. What is Protalix BioTherapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 12 month price objectives for Protalix BioTherapeutics' shares. Their PLX share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 736.8% from the stock's current price. View analysts price targets for PLX or view top-rated stocks among Wall Street analysts. How have PLX shares performed in 2024? Protalix BioTherapeutics' stock was trading at $1.78 at the start of the year. Since then, PLX shares have decreased by 32.9% and is now trading at $1.1950. View the best growth stocks for 2024 here. When is Protalix BioTherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our PLX earnings forecast. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) announced its earnings results on Thursday, March, 14th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.04. The business had revenue of $10.49 million for the quarter, compared to analysts' expectations of $8.15 million. Protalix BioTherapeutics had a net margin of 12.69% and a trailing twelve-month return on equity of 29.73%. When did Protalix BioTherapeutics' stock split? Protalix BioTherapeutics shares reverse split before market open on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PLX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
